The interferon-free combination of the protease inhibitor ABT-450 with ritonavir ( ABT-450 / r ) and the NS5A inhibitor ombitasvir ( also known as ABT-267 ) plus the nonnucleoside polymerase inhibitor dasabuvir ( also known as ABT-333 ) and ribavirin has shown efficacy against the hepatitis C virus ( HCV ) in patients with HCV genotype 1 infection .